Consolidated Statements of Operations (Unaudited) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Revenues:
Product sales	$ 53,161	$ 71,479	$ 87,518	$ 77,076
Contracts and grants	17,218	16,662	33,172	29,598
Total revenues	70,379	88,141	120,690	106,674
Operating expenses:
Cost of product sales	13,186	16,069	20,697	17,137
Research and development	30,645	31,481	56,891	66,240
Selling, general and administrative	17,895	20,384	37,387	38,596
Impairment of in-process research and development	0	0	9,600	0
Income (loss) from operations	8,653	20,207	(3,885)	(15,299)
Other income (expense):
Interest income	29	24	54	59
Interest expense	0	(6)	(6)	(6)
Other income (expense), net	907	(39)	1,761	(40)
Total other income (expense)	936	(21)	1,809	13
Income (loss) before provision for (benefit from) income taxes	9,589	20,186	(2,076)	(15,286)
Provision for (benefit from) income taxes	4,043	7,663	403	(4,636)
Net income (loss)	5,546	12,523	(2,479)	(10,650)
Net loss attributable to noncontrolling interest	2,086	1,687	3,279	3,463
Net income (loss) attributable to Emergent BioSolutions Inc.	$ 7,632	$ 14,210	$ 800	$ (7,187)
Income (loss) per share - basic (in dollars per share)	$ 0.21	$ 0.40	$ 0.02	$ (0.2)
Income (loss) per share - diluted (in dollars per share)	$ 0.21	$ 0.39	$ 0.02	$ (0.2)
Weighted-average number of shares - basic (in shares)	36,182,826	35,619,514	36,114,400	35,400,906
Weighted-average number of shares - diluted (in shares)	36,556,697	36,667,452	36,301,335	35,400,906